keyword
MENU ▼
Read by QxMD icon Read
search

Omalizumab

keyword
https://www.readbyqxmd.com/read/29136264/biological-and-clinical-response-to-omalizumab-in-a-patient-with-bullous-pemphigoid
#1
Sébastien Menzinger, Gürkan Kaya, Enno Schmidt, Lionel Fontao, Emmanuel Laffitte
No abstract text is available yet for this article.
November 14, 2017: Acta Dermato-venereologica
https://www.readbyqxmd.com/read/29132956/the-xtend-ciu-study-long-term-use-of-omalizumab-in-chronic-idiopathic-urticaria
#2
Marcus Maurer, Allen Kaplan, Karin Rosén, Michael Holden, Ahmar Iqbal, Benjamin L Trzaskoma, Ming Yang, Thomas B Casale
These data support omalizumab safety and efficacy in patients with antihistamine-resistant CIU/CSU to 48 weeks and provide evidence of omalizumab re-treatment efficacy and safety.
November 10, 2017: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/29131038/bullous-diseases
#3
Caroline Corbaux, Pascal Joly
Autoimmune bullous diseases are a heterogeneous group of blistering diseases affecting the skin and/or mucous membrane. Systemic corticosteroids, which are often associated with immunosuppressants, are the main treatment option for these diseases. The 2 main biologics used in the treatment of autoimmune bullous diseases are rituximab, especially in pemphigus and mucous membrane pemphigoid, and omalizumab in bullous pemphigoid. Rituximab is a promising therapeutic option in pemphigus and mucous membrane pemphigoid...
2018: Current Problems in Dermatology
https://www.readbyqxmd.com/read/29128337/the-urticaria-activity-score-validity-reliability-and-responsiveness
#4
Tomasz Hawro, Tatevik Ohanyan, Nicole Schoepke, Martin Metz, Adriane Peveling-Oberhag, Petra Staubach, Marcus Maurer, Karsten Weller
BACKGROUND: Chronic spontaneous urticaria is characterized by fluctuating symptoms. Its activity is assessed with the urticaria activity score (UAS). Two versions of the urticaria activity score used for 7 consecutive days (UAS7) are available: (1) The guideline-recommended UAS7, with once-daily documentation, and (2) the UAS7TD, with twice-daily documentation. OBJECTIVE: To better characterize both UAS7 versions with regard to their validity, reliability, sensitivity to change, minimal important difference (MID), and smallest detectable change (SDC)...
November 8, 2017: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/29102514/efficacy-and-safety-of-omalizumab-for-the-treatment-of-refractory-chronic-spontaneous-urticaria-in-japanese-patients-subgroup-analysis-of-the-phase-3-polaris-study
#5
Michihiro Hide, Atsuyuki Igarashi, Akiko Yagami, Yuko Chinuki, Naoko Inomata, Atsushi Fukunaga, Guenther Kaiser, Junyi Wang, Soichiro Matsushima, Steven Greenberg, Sam Khalil
BACKGROUND: Omalizumab, a humanized anti-IgE monoclonal antibody, proved efficacious and well tolerated in patients with chronic spontaneous urticaria (CSU) refractory to H1 antihistamines (H1AH) in the POLARIS study (NCT02329223), a randomized, double-blind, placebo-controlled trial in East Asian patients. However, data in Japanese patients, who have specific baseline characteristics (e.g., low angioedema incidence, different background medications) that may impact clinical outcomes, are lacking...
November 1, 2017: Allergology International: Official Journal of the Japanese Society of Allergology
https://www.readbyqxmd.com/read/29098604/are-biologics-efficacious-in-atopic-dermatitis-a-systematic-review-and-meta-analysis
#6
REVIEW
Igor Snast, Ofer Reiter, Emmilia Hodak, Rivka Friedland, Daniel Mimouni, Yael Anne Leshem
BACKGROUND: Current systemic treatments for atopic dermatitis (AD) offer limited efficacy and are often restricted by safety concerns. Biologics may address the unmet need for improved AD therapeutics. OBJECTIVE: The aim of this study was to evaluate the efficacy and safety of biologic agents in AD. METHODS: A systematic review and meta-analysis of studies evaluating AD patients treated with biologics was performed. The primary outcome was the Eczema Area and Severity Index (EASI)-75 response, while secondary outcomes were SCOring Atopic Dermatitis (SCORAD)-75, EASI-50, SCORAD-50, Investigator Global Assessment 0/1 responses, change in responses from baseline, and adverse events...
November 2, 2017: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/29096848/immunoadsorption-for-treatment-of-severe-atopic-dermatitis
#7
Joanna Wegner, Julia Weinmann-Menke, Esther von Stebut
Atopic dermatitis (AD) is a common disease affecting up to 10-20% of the population with the largest disease burden in childhood. Treatment options include basic emollient treatment, topical as well as systemic immunosuppressants. The pathogenesis is complex and among various triggers, genetic predisposition and immunological alterations contribute to development of disease. Atopy is common in patients with AD and many patients have high levels of Immunoglobulin E (IgE), some of which recognizes exogenous or auto/self-allergens...
November 2017: Atherosclerosis. Supplements
https://www.readbyqxmd.com/read/29083482/the-clinical-response-to-omalizumab-in-csu-patients-is-linked-to-and-predicted-by-ige-levels-and-their-change
#8
Ragip Ertas, Kemal Ozyurt, Mustafa Atasoy, Tomasz Hawro, Marcus Maurer
BACKGROUND: Omalizumab is an effective and well-tolerated treatment for chronic spontaneous urticaria (CSU). Markers and predictors of response are largely unknown, but needed to optimize omalizumab treatment. Omalizumab targets IgE, and IgE levels may be linked to the effects of treatment. We evaluated if response rates to treatment with omalizumab in patients with CSU are linked to their baseline IgE levels, their IgE levels after omalizumab treatment, and the ratio of on treatment IgE and baseline IgE levels...
October 30, 2017: Allergy
https://www.readbyqxmd.com/read/29083477/intranasal-administration-of-allergen-increases-specific-ige-whereas-intranasal-omalizumab-does-not-increase-serum-ige-levels-a-pilot-study
#9
Julia Eckl-Dorna, Renate Fröschl, Christian Lupinek, Renata Kiss, Pia Gattinger, Katharina Marth, Raffaela Campana, Katharina Blatt, Peter Valent, Regina Selb, Andrea Mayer, Katharina Gangl, Irene Steiner, Jutta Gamper, Thomas Perkmann, Petra Zieglmayer, Philippe Gevaert, Rudolf Valenta, Verena Niederberger
BACKGROUND: Administration of the therapeutic anti-IgE antibody omalizumab to patients induces strong increases of IgE antibody levels. OBJECTIVE: To investigate the effect of intranasal administration of major birch pollen allergen Bet v 1, omalizumab or placebo on the levels of total and allergen-specific IgE in patients with birch pollen allergy. METHODS: Based on the fact that intranasal allergen application induces rises of systemic allergen-specific IgE we performed a double-blind placebo-controlled pilot trial in which birch pollen allergic subjects were challenged intranasally with omalizumab, placebo or birch pollen allergen Bet v 1...
October 30, 2017: Allergy
https://www.readbyqxmd.com/read/29079610/duration-of-the-efficacy-of-omalizumab-after-treatment-discontinuation-in-real-life-severe-asthma
#10
Maria Del Carmen Vennera, Carlos Sabadell, Cesar Picado
Efficacy of omalizumab in severe asthma is well documented; however, the optimal duration of the treatment remains unclear. In an open prospective study, we sought to assess the persistence of response in subjects withdrawing from omalizumab treatment. We evaluated 49 patients who voluntarily accepted to discontinue omalizumab treatment after 6 years of therapy. Asthma relapse was defined as any severe asthma exacerbation associated with loss of asthma control. Twelve patients relapsed in the first year of follow-up, and 7 within 13 and 48 months...
October 27, 2017: Thorax
https://www.readbyqxmd.com/read/29070274/long-term-omalizumab-use-in-the-treatment-of-exercise-induced-anaphylaxis
#11
Mark R Peterson, Christopher A Coop
Reported is a case of a 39-year-old male who was diagnosed with exercise-induced anaphylaxis (EIA). He was initially treated prophylactically with fexofenadine, montelukast, and ranitidine. He also used an epinephrine autoinjector as needed. He was refractory to these medications and continued to have episodes of EIA. He was then started on a trial of omalizumab, an immunoglobulin E monoclonal antibody, and had resolution of the EIA episodes. After discontinuation of the omalizumab, the EIA episodes returned...
October 1, 2017: Allergy & Rhinology
https://www.readbyqxmd.com/read/29064325/real-world-treatment-patterns-and-outcomes-of-omalizumab-use-in-patients-with-chronic-idiopathic-urticaria
#12
Liya Wang, Xuehua Ke, Abhishek Kavati, Debra Wertz, Qing Huang, Vincent J Willey, Judith J Stephenson, Benjamin Ortiz, Brandee Paknis, Jonathan A Bernstein, Lisa A Beck
OBJECTIVE: To examine treatment patterns, treatment response, and demographic and clinical characteristics of patients with chronic idiopathic urticaria (CIU) newly initiated on omalizumab therapy in real-world practice in the US. METHODS: This retrospective observational cohort study used US claims data from the HealthCore Integrated Research Database (HIRD(®)) augmented with medical record data to identify CIU patients newly-treated with omalizumab (≥4 omalizumab claims within 6 months of initial claim; index date = first omalizumab claim date) between March 21, 2014 and October 31, 2015 and with ≥6 months pre- and ≥12 months post-index health plan eligibility...
November 10, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29059087/controversies-and-opportunities-in-severe-asthma
#13
Marc Humbert, William Busse, Nicola A Hanania
PURPOSE OF REVIEW: Despite currently available treatments, many asthma patients remain inadequately controlled, but identifying distinct patient populations (phenotypes/endotypes) may optimize their management. This review discusses some of the controversies and opportunities for improved disease control in severe asthma. RECENT FINDINGS: Currently approved anti-immunoglobulin E and anti-interleukin 5 biologics, which target specific pathways instead of using a 'one size fits all' strategy, are efficacious and well tolerated therapies for severe asthma...
October 20, 2017: Current Opinion in Pulmonary Medicine
https://www.readbyqxmd.com/read/29058822/omalizumab-rapidly-improves-angioedema-related-quality-of-life-in-adult-patients-with-chronic-spontaneous-urticaria-x-act-study-data
#14
Petra Staubach, Martin Metz, Nadine Chapman-Rothe, Christian Sieder, Matthias Bräutigam, Marcus Maurer, Karsten Weller
BACKGROUND: The X-ACT study aims to examine the effect of omalizumab treatment on quality of life (QoL) in chronic spontaneous urticaria (CSU) patients with angioedema refractory to high doses of H1 -antihistamines. METHODS: In X-ACT, a phase III, double-blind, placebo-controlled study, CSU patients (18-75 years) with ≥4 angioedema episodes during the 6 months before inclusion were randomized (1:1) to receive omalizumab 300 mg or placebo every 4 weeks for 28 weeks...
October 23, 2017: Allergy
https://www.readbyqxmd.com/read/29057743/omalizumab-as-third-line-therapy-for-urticaria-during-pregnancy
#15
L F Ensina, A P Cusato-Ensina, I C Camelo-Nunes, D Solé
No abstract text is available yet for this article.
2017: Journal of Investigational Allergology & Clinical Immunology
https://www.readbyqxmd.com/read/29057669/patient-reported-outcomes-in-moderate-to-severe-allergic-asthmatics-treated-with-omalizumab-a-systematic-literature-review-of-randomized-controlled-trials
#16
Jonathan Corren, Abhishek Kavati, Benjamin Ortiz, Ashok Vegesna, Jennifer A Colby, Kimberly Ruiz, Reynold A Panettieri
OBJECTIVE: Randomized controlled trials (RCTs) have established the safety and efficacy of omalizumab on clinical parameters, and have also evaluated its impact on patient-reported outcomes (PROs). The purpose of this systematic literature review was to review published data based on PRO endpoints in order to determine the benefit of omalizumab as add-on therapy to inhaled corticosteroids in patients with moderate-to-severe persistent allergic asthma. METHODS: A systematic literature review was conducted of reference databases and recent conferences...
October 23, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29054589/baseline-asthma-burden-comorbidities-and-biomarkers-in-omalizumab-treated-patients-in-prospero
#17
Bradley E Chipps, Robert S Zeiger, Allan T Luskin, William W Busse, Benjamin L Trzaskoma, Evgeniya N Antonova, Hooman Pazwash, Susan L Limb, Paul G Solari, Noelle M Griffin, Thomas B Casale
BACKGROUND: Patients included in clinical trials do not necessarily reflect the real-world population. OBJECTIVE: To understand the characteristics, including disease and comorbidity burden, of patients with asthma receiving omalizumab in a real-world setting. METHODS: The Prospective Observational Study to Evaluate Predictors of Clinical Effectiveness in Response to Omalizumab (PROSPERO) was a US-based, multicenter, single-arm, and prospective study...
October 17, 2017: Annals of Allergy, Asthma & Immunology
https://www.readbyqxmd.com/read/29044681/does-omalizumab-modify-a-course-of-recalcitrant-chronic-spontaneous-urticaria-a-retrospective-study-in-asian-patients
#18
Kanokvalai Kulthanan, Papapit Tuchinda, Chayanee Likitwattananurak, Puncharas Weerasubpong, Leena Chularojanamontri
Omalizumab has been approved for the treatment of recalcitrant chronic spontaneous urticaria (CSU). However, it remains unanswered whether omalizumab modifies a CSU course. We aimed to study a course of CSU after omalizumab treatment in an Asian population. Medical records of recalcitrant CSU patients who attended Siriraj Hospital between 2013 and 2017 were reviewed. All patients receiving omalizumab treatment were followed after the first injection for at least 1 year. Of 15 patients receiving omalizumab treatment, 11 patients (73...
October 17, 2017: Journal of Dermatology
https://www.readbyqxmd.com/read/29044640/a-step-down-protocol-for-omalizumab-treatment-in-oral-corticosteroid-dependent-allergic-asthma-patients
#19
Christian Domingo, Xavier Pomares, Albert Navarro, María José Amengual, Concepción Montón, Ana Sogo, Rosa M Mirapeix
BACKGROUND: there are no specific criteria for a step-down or withdrawal dose of omalizumab. Our purpose was to evaluate the viability of a protocol for OMAlizumab DOse REduction (the OMADORE study) in severe allergic asthma (SAA). METHODS: the study population included 35 SAA patients treated during a minimum period of one year with oral corticosteroids (OC) equivalent to a mean daily dose of 4 mg of methyl-prednisolone. To qualify for the protocol, the patients had to have received treatment with OMA ≥ one year and a half, OC dose had to have reached the lowest tolerated dose and spirometry had to be ≥ at entry...
October 18, 2017: British Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/29037993/omalizumab-response-in-patients-with-chronic-idiopathic-urticaria-insights-from-the-xtend-ciu-study
#20
Thomas B Casale, Patrick H Win, Jonathan A Bernstein, Karin Rosén, Michael Holden, Ahmar Iqbal, Benjamin L Trzaskoma, Ming Yang, Evgeniya N Antonova, Thomas Murphy, Mark D Scarupa, Howard Sofen, Allen Kaplan
No abstract text is available yet for this article.
October 13, 2017: Journal of the American Academy of Dermatology
keyword
keyword
7812
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"